The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials.
 
Shivaani Kummar
Stock and Other Ownership Interests - Arxeon Therapeutics (I); PathomIQ
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Cadila Pharmaceuticals (I); EcoR1 Capital; Gilead Sciences; Harbour BioMed; Mirati Therapeutics; Mundipharma; Oxford BioTherapeutics; Seagen; SpringWorks Therapeutics
Research Funding - ADC Therapeutics (Inst); ADC Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Day One Therapeutics (Inst); Dynavax Technologies (Inst); Elevation Oncology (Inst); Genome & Company (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Moderna Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Plexxikon (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Bayer
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squib; Daiichi Sankyo; Harbour BioMed; Merck; Mingji biopharmaceutical; MSD; Roche
Speakers' Bureau - Hutchison Whampoa; MSD
Research Funding - Baiji Shenzhou (Beijing) Biotechnology (Inst); Beijing Xiantong Biomedical Technology (Inst); Nanjing Yaojieankang Biotechnology (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical (Inst)
 
Cornelis Martinus van Tilburg
Consulting or Advisory Role - Bayer; Novartis
 
Daniel S.W. Tan
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Loxo; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; GlaxoSmithKline; Novartis
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Francois Doz
Consulting or Advisory Role - SERVIER (Inst)
Travel, Accommodations, Expenses - Bayer (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
C. Michel Zwaan
Consulting or Advisory Role - Incyte; Novartis; Roche; Sanofi; Takeda
Research Funding - Abbvie (Inst); Jazz Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Jazz Pharmaceuticals
 
Karen N. Keating
Employment - Bayer
 
Costel Chirila
Employment - RTI International
 
Ricarda Norenberg
Employment - Bayer Health (I)
Consulting or Advisory Role - Bayer Health (Inst)
 
Marc Mardoche Fellous
Employment - Bayer
Consulting or Advisory Role - Bayer (I)
 
Nicoletta Brega
Employment - Bayer; Bayer; Bayer; Bayer
Leadership - Bayer
Stock and Other Ownership Interests - Bayer
Travel, Accommodations, Expenses - Bayer
Other Relationship - Bayer
 
Rui-hua Xu
No Relationships to Disclose
 
Theodore Willis Laetsch
Consulting or Advisory Role - Advanced Microbubbles; AI Therapeutics; Aptitude Health; Bayer; Cellectis; Clinical Education Alliance; Deciphera; Jazz Pharmaceuticals; Jumo Health; Massive Bio; Med Learning Group; Medscape; Novartis; Physicans' Education Resource; Y-mAbs Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Epizyme (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Jubilant Pharmaceuticals (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novella Clinical (Inst); Pfizer (Inst); SERVIER (Inst); Turning Point Therapeutics (Inst)
 
Alexander E. Drilon
Stock and Other Ownership Interests - Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV More; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Infinity Pharmaceuticals; Janssen; Liberum; MedaCorp; Medscape; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer; Telperian